LONDON – Intellectual property commercialization specialist Frontier IP Group PLC (FIPP.LN) Monday said its portfolio company Exscientia Ltd yesterday announced that it has entered into a strategic drug discovery collaboration with GlaxoSmithKline PLC (GSK.LN).
Continue Reading Below
Shares at 0801 GMT, up 4 pence, or 11.8%, at 43 pence valuing the company at GBP16.3 million
-Write to Rory Gallivan at firstname.lastname@example.org; Twitter: @RoryGallivan
(END) Dow Jones Newswires
July 03, 2017 04:17 ET (08:17 GMT)